Philip Grant
Key Documents
Contact Information
-
Clinical Offices
Positive Care Clinic 3351 El Camino Real Suite 225 Atherton, CA 94027 Tel Work (650) 723-9001 Fax (650) 568-1708
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Infectious Disease
Professional Education
| Fellowship: | Stanford University - Infectious Diseases CA (2010) |
| Fellowship: | Stanford University - Infectious Diseases CA (2008) |
| Board Certification: | Infectious Disease, American Board of Internal Medicine (2008) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2003) |
| Residency: | University of Washington Medical Center, WA USA (2003) |
Scientific Focus
Clinical Trials
- The Stanford HIV Aging Group (SHAG) Recruiting
- A5281: A Phase I Randomized, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a Cytokine Enhanced HIV-1 Multi-Antigen (HIV MAG) pDNA Vaccine Delivered Intramuscularly Followed by in Vivo Electroporation (IM/EP) or Intramuscularly in HIHIV-1 Infected Adults Receiving ART Recruiting
- A5286: A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy Recruiting
- A5296: Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study Recruiting
- A5303: A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel, Maraviroc-containing Antiretroviral Regimen in Treatment-Na·ve Patients Infected with R5-tropic HIV-1 Recruiting
Publications
- Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS. 2011; (2): 211-20
- Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clin Infect Dis. 2010; (8): 984-5; author reply 987-9
- International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother. 2010; (4): 1520-5
- Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Curr Opin Investig Drugs. 2010; (8): 901-10
- Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010; (6): 2473-9
Help